坦昔妥单抗(Tafasitamab-Cxix) - 药物靶点：CD19_在研适应症：复发性滤泡性淋巴瘤，难治性滤泡性淋巴瘤，弥漫性大B细胞淋巴瘤_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

anti-CD19 MAb XmAb5574、anti-CD19 MoAb XmAb5574、Tafasitamab

+ [12]

靶点

CD19

作用方式

抑制剂

作用机制

CD19抑制剂(B淋巴细胞抗原CD19抑制剂)、ADCC(抗体依赖的细胞毒作用)、抗体依赖的细胞吞噬作用

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [1]

在研适应症

复发性滤泡性淋巴瘤难治性滤泡性淋巴瘤弥漫性大B细胞淋巴瘤+ [28]

非在研适应症

难治性套细胞淋巴瘤

原研机构

Xencor, Inc.

在研机构

Incyte Corp.

北京诺诚健华医药科技有限公司Specialised Therapeutics Australia Pty Ltd.

+ [6]

非在研机构

Xencor, Inc.

权益机构

Incyte Corp.Specialised Therapeutics Asia Pte Ltd.

Knight Therapeutics, Inc.

+ [6]

最高研发阶段批准上市

首次获批日期

美国 (2020-07-31),

难治性弥漫性大 B 细胞淋巴瘤

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、快速通道 (美国)、加速批准 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)、孤儿药 (日本)、孤儿药 (韩国)、孤儿药 (澳大利亚)、附条件批准 (欧盟)、附条件批准 (美国)、附条件批准 (中国)

登录后查看时间轴

结构/序列

Sequence Code 1697872

来源: *****

Sequence Code 12960725

来源: *****

关联

58

项与坦昔妥单抗相关的临床试验

NCT07104565

/ Recruiting临床2期

A Phase 2a, Open-Label, Multicenter Study of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.

开始日期2025-12-29

申办/合作机构

Incyte Corp.

NCT07225439

/ Not yet recruiting临床1期IIT

Phase I Clinical Trial of Rituximab (Rtx) and Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma

This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy. The purpose of this study is to identify the recommended dose of allogeneic NK cells in combination with IL-2, Tafasitamab and Rituximab for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
NK cells are an investigational (experimental) treatment which means they are not approved by the Food and Drug Administration (FDA). NK cells are a type of lymphocyte that's part of the body's natural immune system, and they can kill cancer cells by creating pores in the cancer cell membranes and inducing apoptosis (programmed cell death).
Participants in this study will receive lymphodepleting chemotherapy, as well as Allogeneic NK cells, Tafasitamab and Interleukin-2 (IL-2) by an intravenous (IV) infusion. Participants are expected to complete one cycle, and they may be eligible to complete a second cycle of the same regiment if they have stable disease, partial or complete remission at the end of the first cycle. Participants will be in this study for about 12 months.

开始日期2025-12-01

申办/合作机构

The Case Comprehensive Cancer Center

[+1]

NCT07030699

/ Recruiting临床2期IIT

Epcoritamab With Lenalidomide and Tafasitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL)

The researchers are doing this study to find out whether the combination of epcoritamab with tafasitamab and lenalidomide is a safe and effective treatment for relapsed or refractory DLBCL. This is the first time the combination of drugs is being tested.

开始日期2025-08-13

申办/合作机构

Memorial Sloan Kettering Cancer Center

[+2]

100 项与坦昔妥单抗相关的临床结果

登录后查看更多信息

100 项与坦昔妥单抗相关的转化医学

登录后查看更多信息

100 项与坦昔妥单抗相关的专利（医药）

登录后查看更多信息

119

项与坦昔妥单抗相关的文献（医药）

2026-02-01·ANTI-CANCER DRUGS

Anti-CD19 antibody tafasitamab therapy for relapsed or refractory diffuse large B-cell lymphoma: a case series

Article

作者: Yi, Hongmei ; Zhao, Weili ; Zhang, Mengping ; Chen, Wenting ; Xing, Tingting ; Yan, Zixun ; Xu, Pengpeng ; Wang, Zhi ; Feng, Yuan ; You, Jianhua ; Tian, Dengmei

Tafasitamab, an anti-CD19 mAb, has demonstrated promising efficacy in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in Western populations, but its use in Chinese patients has not been reported. This case series reports the use of tafasitamab in four Chinese patients with R/R DLBCL. Four patients with R/R DLBCL were treated at the Department of Hematology, Hainan Hospital of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. All patients had previously received rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone therapy. After treatment with tafasitamab and lenalidomide, two patients with primary refractory disease, one achieved a partial response and another had stable disease. One patient who relapsed after autologous stem-cell transplantation received tafasitamab plus lenalidomide and a Bruton tyrosine kinase (BTK) inhibitor and showed remarkable tumor reduction in all sites except for the lymph nodes in the left inguinal region. One patient who relapsed after second-line therapy achieved complete remission with tafasitamab monotherapy. Tafasitamab-based treatment was well-tolerated, with the most common adverse event being neutropenia. Our real-world experience first suggests that tafasitamab-based flexible treatment may be a potential treatment option for Chinese patients with R/R DLBCL, supporting the need for further investigation into its efficacy and safety in Chinese patients, with a particular focus on exploring directions such as combinations with BTK inhibitors.

2026-01-27·CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Tafasitamab interference in immunofixation electrophoresis

Letter

作者: Fink, Susan L. ; Treger, Rebecca S.

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States

Article

作者: Li, Jia ; Mahmoudjafari, Zahra ; Masaquel, Anthony ; Parisé, Hélène ; Bercaw, Eric ; Bognar, Katalin ; Wang, Si-Tien

BACKGROUND:

Glofitamab is a T-cell engaging bispecific monoclonal antibody that was granted accelerated approval from the United States Food and Drug Administration for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after ≥2 lines of systemic therapy (3L+).

METHODS:

A budget impact model was developed for a hypothetical blended commercial/Medicare health plan with 1,000,000 members. Comparators were axicabtagene ciloleucel (Axi-cel), lisocabtagene maraleucel (Liso-cel), tisagenlecleucel (Tisa-cel), loncastuximab tesirine, polatuzumab vedotin + bendamustine + rituximab, rituximab + gemcitabine + oxaliplatin, tafasitamab + lenalidomide, and epcoritamab (Epcor). Total costs included those for drugs, wastage, administration, grade ≥3 adverse reactions, and all-grade cytokine release syndrome) and routine care. Market shares were based on internal projections and expert opinions. Total and per-member per-month (PMPM) net budget impacts over 3 years were calculated.

RESULTS:

Approximately nine patients were projected to be eligible for 3L + DLBCL treatment in a health plan of 1,000,000 members. The introduction of glofitamab as a treatment option resulted in estimated total and PMPM cost savings of $728,697 and -$0.0202, respectively, over 3 years. Costs were reduced across all cost categories but particularly in drug costs. Among the newer therapies, total 3-year cost per treated patient was lowest for glofitamab: $226,658 versus Tisa-cel = $564,113; Axi-cel = $540,002; Liso-cel = $516,272; and Epcor = $335,293. Across all sensitivity analyses, the inclusion of glofitamab had minimal PMPM budget impact, ranging from -$0.0256 to -$0.0108.

CONCLUSIONS:

With the lowest 3-year total cost per treated patient among the newer therapies, glofitamab being an available option in the 3L + DLBCL market is estimated to save a hypothetical 1,000,000-member health plan $728,697 in cumulative total costs and $0.0202 in PMPM costs over 3 years.

463

项与坦昔妥单抗相关的新闻（医药）

2026-01-07

·手机新浪网

诺诚健华涨3.49%，成交额2.06亿元，今日主力净流入489.44万

1月7日，诺诚健华涨3.49%，成交额2.06亿元，换手率3.57%，总市值382.05亿元。异动分析创新药1、据招股说明书：公司的主要产品之一奥布替尼（宜诺凯?）已获得国家药监局附条件批准上市用于治疗复发或难治性 MCL 和复发或难治性 CLL/SLL。根据奥布替尼的《药品注册证书》，公司需要在奥布替尼上市后完成 III 期确证性临床试验。在完成上述确证性临床试验后，奥布替尼方能获得完全批准。(免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断)资金分析今日主力净流入489.44万，占比0.02%，行业排名29/158，该股当前无连续增减仓现象，主力趋势不明显；所属行业主力净流入-4.94亿，连续2日被主力资金减仓。区间今日近3日近5日近10日近20日主力净流入489.44万-1295.47万-2484.09万-9549.85万-2.33亿主力持仓主力没有控盘，筹码分布非常分散，主力成交额4612.74万，占总成交额的6.36%。技术面：筹码平均交易成本为24.26元该股筹码平均交易成本为24.26元，近期筹码减仓，但减仓程度减缓；目前股价靠近支撑位21.59，注意支撑位处反弹，若跌破支撑位则可能会开启一波下跌行情。公司简介资料显示，诺诚健华医药有限公司位于北京市昌平区中关村生命科学园生命园路8号院8号楼，成立日期2015年11月3日，上市日期2022年9月21日，公司主营业务涉及诺诚健华医药有限公司是一家主要从事生物医药的研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在未满足临床需求的领域，其产品管线包括ICP-022、ICP-B04、ICP-490、ICP-192、ICP-723、ICP-022等。该公司主要在中国和美国开展业务。主营业务收入构成为：药品销售87.67%，技术授权12.04%，检测服务0.15%，研发服务0.15%。诺诚健华所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：抗癌药物、抗癌治癌、生物医药、创新药、基金重仓等。截至9月30日，诺诚健华股东户数1.65万，较上期增加8.66%；人均流通股0股，较上期增加0.00%。2025年1月-9月，诺诚健华实现营业收入11.15亿元，同比增长59.85%；归母净利润-6441.49万元，同比增长76.61%。机构持仓方面，截止2025年9月30日，诺诚健华十大流通股东中，富国精准医疗灵活配置混合A（005176）位居第六大流通股东，持股1215.49万股，相比上期减少42.71万股。万家优选（161903）位居第七大流通股东，持股1000.00万股，为新进股东。平安医疗健康混合A（003032）位居第八大流通股东，持股862.66万股，为新进股东。工银前沿医疗股票A（001717）位居第九大流通股东，持股800.00万股，为新进股东。汇添富创新医药混合A（006113）位居第十大流通股东，持股686.03万股，相比上期减少74.34万股。中欧医疗健康混合A（003095）、鹏华医药科技股票A（001230）、易方达医疗保健行业混合A（110023）退出十大流通股东之列。风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建议。

财报临床3期申请上市IPO临床1期

2026-01-06

·新浪看点

诺诚健华跌2.65%，成交额2.02亿元，近3日主力净流入-2117.97万

1月6日，诺诚健华跌2.65%，成交额2.02亿元，换手率3.59%，总市值369.16亿元。异动分析创新药1、据招股说明书：公司的主要产品之一奥布替尼（宜诺凯?）已获得国家药监局附条件批准上市用于治疗复发或难治性 MCL 和复发或难治性 CLL/SLL。根据奥布替尼的《药品注册证书》，公司需要在奥布替尼上市后完成 III 期确证性临床试验。在完成上述确证性临床试验后，奥布替尼方能获得完全批准。(免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断)资金分析今日主力净流入-1838.04万，占比0.1%，行业排名140/158，连续3日被主力资金减仓；所属行业主力净流入-9.19亿，当前无连续增减仓现象，主力趋势不明显。区间今日近3日近5日近10日近20日主力净流入-1670.79万-2117.97万-2729.19万-9982.32万-2.38亿主力持仓主力没有控盘，筹码分布非常分散，主力成交额5102.59万，占总成交额的7.29%。技术面：筹码平均交易成本为24.38元该股筹码平均交易成本为24.38元，近期筹码减仓，但减仓程度减缓；目前股价在压力位21.74和支撑位20.28之间，可以做区间波段。公司简介资料显示，诺诚健华医药有限公司位于北京市昌平区中关村生命科学园生命园路8号院8号楼，成立日期2015年11月3日，上市日期2022年9月21日，公司主营业务涉及诺诚健华医药有限公司是一家主要从事生物医药的研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在未满足临床需求的领域，其产品管线包括ICP-022、ICP-B04、ICP-490、ICP-192、ICP-723、ICP-022等。该公司主要在中国和美国开展业务。主营业务收入构成为：药品销售87.67%，技术授权12.04%，检测服务0.15%，研发服务0.15%。诺诚健华所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：抗癌治癌、抗癌药物、生物医药、创新药、基金重仓等。截至9月30日，诺诚健华股东户数1.65万，较上期增加8.66%；人均流通股0股，较上期增加0.00%。2025年1月-9月，诺诚健华实现营业收入11.15亿元，同比增长59.85%；归母净利润-6441.49万元，同比增长76.61%。机构持仓方面，截止2025年9月30日，诺诚健华十大流通股东中，富国精准医疗灵活配置混合A（005176）位居第六大流通股东，持股1215.49万股，相比上期减少42.71万股。万家优选（161903）位居第七大流通股东，持股1000.00万股，为新进股东。平安医疗健康混合A（003032）位居第八大流通股东，持股862.66万股，为新进股东。工银前沿医疗股票A（001717）位居第九大流通股东，持股800.00万股，为新进股东。汇添富创新医药混合A（006113）位居第十大流通股东，持股686.03万股，相比上期减少74.34万股。中欧医疗健康混合A（003095）、鹏华医药科技股票A（001230）、易方达医疗保健行业混合A（110023）退出十大流通股东之列。风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建议。

2026-01-06

·Firstwordpharma

Incyte's Monjuvi poised for first-line DLBCL expansion after pivotal study win

Incyte's Monjuvi (tafasitamab) met the primary endpoint of a pivotal study for the first-line treatment of adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL), setting up a marketing application to the FDA in the first half of the year. The Phase III frontMIND trial enrolled around 900 adults with newly diagnosed DLBCL with an International Prognostic Index (IPI) score of three to five for patients >60 years of age, or age-adjusted IPI of two to three for patients ≤60 years of age. Participants were randomised to receive Monjuvi and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared with R-CHOP alone.Top-line results showed that the study's main goal of progression-free survival (PFS) was achieved, with a 25% reduction in the risk of progression or death, while the key secondary endpoint of event-free survival was also hit. Incyte noted that no new safety signals were seen in the trial.Chief Medical Officer Steven Stein said the findings, which will be presented at an upcoming scientific meeting, offer "the possibility of cures for more newly diagnosed DLBCL patients." Monjuvi, also known as Minjuvi, is approved in the US and EU in combination with lenalidomide for adults with relapsed or refractory DLBCL not otherwise specified including DLBCL arising from low-grade lymphoma, and who are not eligible for autologous stem cell transplant. The humanised Fc-modified cytolytic CD19 targeting monoclonal antibody was also cleared last year in the US and EU for use alongside rituximab and lenalidomide in adults with relapsed/refractory follicular lymphoma.For related analysis, see - KOL Views Preview: In light of Phase III win, is Incyte’s Monjuvi a real 1L contender in DLBCL?

临床结果临床3期上市批准细胞疗法免疫疗法

100 项与坦昔妥单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L01XC	DB15044

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
复发性滤泡性淋巴瘤	美国	MorphoSys US, Inc.	2025-06-18
难治性滤泡性淋巴瘤	美国	MorphoSys US, Inc.	2025-06-18
弥漫性大B细胞淋巴瘤	加拿大	Incyte Corp.	2021-12-06
复发性弥漫性大B细胞淋巴瘤	加拿大	Incyte Corp.	2021-08-19
难治性弥漫性大 B 细胞淋巴瘤	美国	MorphoSys US, Inc.	2020-07-31

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
滤泡性淋巴瘤	临床3期	美国	MorphoSys AG	2022-01-30
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	美国	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	日本	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	阿根廷	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	澳大利亚	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	奥地利	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	加拿大	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	哥伦比亚	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	捷克	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	法国	Incyte Corp.	2021-05-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04680052 (inMIND, ASH2025)	临床3期	难治性滤泡性淋巴瘤二线 CD19+ \| CD20+	548	LenalidomideRituximabTafasitamab + LenalidomideRituximabTafasitamabe + LenalidomideRituximabTafasitamab	鏇醖簾廠構觸願選選網(廠積壓繭繭觸鹹糧鬱齋) = 遞鏇壓繭繭憲繭製遞窪壓繭襯夢積鑰艱夢鏇壓 (範鬱膚繭繭鏇憲簾夢觸 ) 更多	积极	2025-12-06
				LenalidomideRituximab + LenalidomideRituximabide + LenalidomideRituximab	鏇醖簾廠構觸願選選網(廠積壓繭繭觸鹹糧鬱齋) = 積壓獵膚糧顧廠積網積壓繭襯夢積鑰艱夢鏇壓 (範鬱膚繭繭鏇憲簾夢觸 ) 更多
NCT05351593 (ASH2025)	临床1/2期	复发性中枢神经系统淋巴瘤	9	Tafasitamab plus lenalidomide	衊蓋觸鬱獵鹹壓襯遞襯(膚鏇遞壓襯糧衊鬱網觸) = febrile neutropenia associated with urinary tract infection 觸膚簾餘糧膚獵淵繭廠 (顧獵夢獵鹹築築選繭衊 )	积极	2025-12-06
NCT04978584 (Smart Stop, ASH2025)	临床2期	弥漫性大B细胞淋巴瘤一线	61	Lenalidomide+Tafasitamab+Rituximab+Acalabrutinib (2 cycles of CHOP)	製鏇觸齋獵鑰糧窪繭鹹(衊衊鑰蓋願糧憲艱繭構) = 鑰壓膚範餘糧網顧製簾淵簾網襯餘鬱鑰餘繭襯 (齋衊獵積鏇憲鬱鹹願鑰 ) 更多	积极	2025-12-06
				Lenalidomide+Tafasitamab+Rituximab+Acalabrutinib (no cycles of CHOP)	製鏇觸齋獵鑰糧窪繭鹹(衊衊鑰蓋願糧憲艱繭構) = 構壓壓醖淵構齋鑰製鬱淵簾網襯餘鬱鑰餘繭襯 (齋衊獵積鏇憲鬱鹹願鑰 ) 更多
NCT05718869 (ASH2025)	临床2期	慢性淋巴细胞白血病 \| 小淋巴细胞淋巴瘤一线	22	TafasitamabZanubrutinib + TafasitamabZanubrutinib	蓋衊築積築膚糧築壓選(獵窪糧選襯蓋憲構積範) = 壓艱齋網襯鹽鑰觸鬱鏇壓網觸壓憲觸憲醖觸鑰 (艱構壓觸醖積淵窪壓遞 ) 更多	积极	2025-12-06
NCT04680052 (inMIND, Pubmed \| Nephron Clin Pract)	临床3期	难治性滤泡性淋巴瘤二线	548	Tafasitamab+lenalidomide+rituximab	觸糧廠製壓鹽構遞齋選(鑰衊簾襯餘襯鬱觸觸鏇) = 簾艱鹽製糧艱選築積鏇襯遞蓋餘窪壓繭製膚廠 (夢鏇簾積鏇獵憲構簾壓 )	积极	2025-12-01
				Placebo+lenalidomide+rituximab	觸糧廠製壓鹽構遞齋選(構齋網壓糧鑰壓淵願齋) = 齋鑰鹽築獵糧膚鏇範積築製膚製簾鑰鏇範顧齋 (糧蓋鹹夢餘築遞壓餘鹽 ) 更多
L-MIND (ESMO2025)	N/A	弥漫性大B细胞淋巴瘤	236	Tafasitamab combined with lenalidomide	糧鑰觸憲艱壓淵憲範淵(繭鬱選衊襯積壓顧鏇壓) = 繭窪齋廠繭願獵窪遞鏇顧鑰齋蓋艱鹽製鏇壓網 (遞遞選築淵鬱簾糧築網 ) 更多	积极	2025-10-17
				Glofitamab	糧鑰觸憲艱壓淵憲範淵(繭鬱選衊襯積壓顧鏇壓) = 糧遞選窪窪範選構膚鹹顧鑰齋蓋艱鹽製鏇壓網 (遞遞選築淵鬱簾糧築網 ) 更多
NCT05222555 (MINDway, CTgov)	临床1/2期	复发性弥漫性大B细胞淋巴瘤	53	Lenalidomide+Tafasitamab (Tafasitamab Dose Level 1 + 25 mg Lenalidomide)	淵鏇襯膚壓餘淵鏇膚獵 = 衊鹹網鏇鏇簾窪壓壓鏇膚獵糧鏇簾壓鹹鹽餘範 (鬱醖餘簾糧淵鏇襯鑰糧, 範鑰窪簾憲鏇範繭鹹淵 ~ 積鏇餘襯醖鏇觸獵夢繭) 更多	-	2025-07-28
				Lenalidomide+Tafasitamab (Tafasitamab Dose Level 2 + 25 mg Lenalidomide)	淵鏇襯膚壓餘淵鏇膚獵 = 範齋鏇簾夢醖範糧願簾膚獵糧鏇簾壓鹹鹽餘範 (鬱醖餘簾糧淵鏇襯鑰糧, 鹹顧衊觸遞鑰鹹願淵構 ~ 膚醖構鹽鑰鬱網遞簾醖) 更多
NCT02763319 (B-MIND, CTgov)	临床2/3期	难治性弥漫性大B细胞淋巴瘤活化B细胞型 \| 复发性弥漫性大B细胞淋巴瘤	453	Tafasitamab+Bendamustine (Tafasitamab + Bendamustine)	窪醖觸膚鏇製網鹹衊鏇(網蓋淵餘願獵範鏇構鏇) = 鹽糧鑰窪鬱夢衊選鹽簾齋廠鏇鏇衊顧夢繭鬱觸 (網膚蓋壓襯簾築鹽餘齋, 壓襯觸遞窪窪壓鹽糧繭 ~ 蓋糧顧鹽鏇夢淵鹽窪蓋) 更多	-	2025-07-17
				Bendamustine+Rituximab (Rituximab + Bendamustine)	窪醖觸膚鏇製網鹹衊鏇(網蓋淵餘願獵範鏇構鏇) = 築願蓋獵艱鏇蓋遞選積齋廠鏇鏇衊顧夢繭鬱觸 (網膚蓋壓襯簾築鹽餘齋, 膚繭觸築鹹鑰齋壓蓋廠 ~ 遞糧憲鏇構鹽壓醖鏇遞) 更多
NCT04680052 (inMIND, FDA_CDER) 人工标引	临床3期	滤泡性淋巴瘤	548	MONJUVI in Combination with Lenalidomide and Rituximab	網襯積鹽膚窪遞鑰蓋齋(廠鹽積鹹選顧鹽夢艱鏇) = 獵築觸壓蓋齋鹽窪簾襯選鑰夢積獵網積製淵鹽 (遞窪壓鬱夢顧鏇範壓顧, 19.2 ~ NE) 更多	积极	2025-06-18
				Placebo in Combination with Lenalidomide and Rituximab	網襯積鹽膚窪遞鑰蓋齋(廠鹽積鹹選顧鹽夢艱鏇) = 願鑰淵糧衊製網憲鏇遞選鑰夢積獵網積製淵鹽 (遞窪壓鬱夢顧鏇範壓顧, 11.5 ~ 16.4) 更多
NCT04680052 (INMIND, EHA2025) 人工标引	临床3期	难治性滤泡性淋巴瘤 CD19 Positive \| CD20 Positive	548	Tafasitamab + Lenalidomide + Rituximab	壓蓋襯鹹鏇範廠遞築廠(鹹壓選蓋鬱選鹹鬱顧鹹) = 餘選齋艱鹹觸糧餘窪網鹹齋網窪艱鹽鏇獵構鑰 (遞鏇餘艱糧範觸觸網齋 ) 更多	积极	2025-05-14
				Placebo + Lenalidomide + Rituximab	壓蓋襯鹹鏇範廠遞築廠(鹹壓選蓋鬱選鹹鬱顧鹹) = 簾膚齋鹹鹽鹽齋鬱積襯鹹齋網窪艱鹽鏇獵構鑰 (遞鏇餘艱糧範觸觸網齋 ) 更多